Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

Drug Effectively Treated 41 to 50% of Patients and Was Well-Tolerated
PRINCETON, NJ, Jun 14, 2007 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced results from its completed Phase 2/3 study of liarozole in lamellar ichthyosis, a rare genetic disorder (incidence of approximately 1 in 200,000) which is characterized by a thick scaling of the skin over large body areas. Study results showed liarozole, dosed at 75 mg and 150 mg per day for 12 weeks, was well-tolerated and "effectively treated" the disorder in 41% and 50% of the patients, respectively. The primary efficacy endpoint, "effectively treated," was defined as the percentage of patients that obtained at least a 2 point reduction in investigator's global assessment (IGA) score as defined on a 5 point scale.

The randomized, double-blind, placebo-controlled dose ranging study enrolled 64 patients in three treatment groups. Patients received placebo, 75 mg or 150 mg of liarozole daily for 12 weeks, randomized 1:3:3, respectively. Response rates for the primary endpoint were 41% (11 of 27 patients) for the 75 mg dose, 50% (14 of 28 patients) for the 150 mg dose and 11% (1 of 9 patients) for placebo. The p-values for the 75 and 150 mg per day groups compared to placebo were p=0.2193 and p=0.0557, respectively.

For the secondary endpoints of mean IGA score at week 8 and the overall scaling score at weeks 8 and 12, both liarozole groups achieved statistically significant differences from placebo (p < 0.05). The mean IGA score at week 8 was reduced by 36% and 43% for the 75 and 150 mg liarozole treatment groups, respectively versus 3% for placebo. The mean IGA score for the two liarozole treatment groups continued to improve through 12 weeks. The mean reduction in overall scaling was approximately 45% for both liarozole treatment
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... Amy Norton HealthDay ... Tonsillectomies are commonly done to relieve sleep apnea in children, ... kids, weight gain -- especially if they,re already overweight. ... risk factor for a range of health problems -- including, ... kids who need it. Instead, they said, doctors and ...
(Date:7/28/2014)... Lourdes Health System has partnered with ... wait times for veterans needing medical care. , Lourdes ... state—and the only one in Camden, Burlington and Gloucester ... program (PC3). PC3 gives veterans access to specialty care ... services due to lack of available specialists, long wait ...
(Date:7/28/2014)... 2014 The American Society ... professionals engaged in the field of organ transplantation, ... and Immunology Research Network (TIRN), a professional ... As modern organ transplantation continues to diversify, AST ... provide more opportunities for physicians, scientists and researchers ...
(Date:7/28/2014)... July 28, 2014 With California in ... is welcome news that a fire blanket ... protection is under development by SunSeeker Enterprises, Inc. The ... protect spacecraft from the extreme heat of re-entry into ... firefighters and homes. , “Our firefighters routinely lay their ...
(Date:7/28/2014)... Boston University School of Medicine (BUSM) report variants in ... of developing Alzheimer,s disease (AD). The discovery of this ... options that target PLXNA4 specifically. These findings appear in ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people age 85 ...
Breaking Medicine News(10 mins):Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Researchers identify potential biomarker for AD 2
... throat strictures, cancer, group warns , FRIDAY, Aug. 31 ... heartburn once a month and more than 15 million ... of Gastroenterology. , Heartburn occurs when stomach contents ... tube that connects the mouth and the stomach. , ...
... to Help Ensure Success, ANAHEIM, Calif., Aug. 31 ... coach Tim Borland,will run a full marathon each day ... to a deadly children,s disease. His "A-T CureTour" -- ... take him,across the country, ending on Nov. 4 with ...
... MTD ) today announced the webcast of its,presentation ... on Friday, September 7, 2007, at 9:10 a.m. Eastern ... the investor relations page on the,Company,s Web site at ... be,available for seven days. METTLER TOLEDO is a ...
... Kan., Aug. 31 Juergen Richt, lead,scientist with ... and an adjunct professor at Iowa State University, ... Distinguished Professor. Richt,s appointment begins in April ... the College of Veterinary,Medicine, is the most prestigious ...
... Inc. (Nasdaq: AMCS ),a leader in radiology and medical image ... investors at the,Thomas Weisel Partners Healthcare Conference 2007 being held in ... -- Thursday, September 6, 2007 ... at 8:35 a.m. (Eastern Time), ...
... shows blocking 2 proteins could mean less invasive treatment ... -- The swelling that normally occurs when a joint ... researchers say. , Publishing in the September issue of ... two immune system proteins -- interleuken-1 and tumor necrosis ...
Cached Medicine News:Health News:Heartburn Can Be a Sign of Serious Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 2Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 3Health News:Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease 4Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 2Health News:Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007 2Health News:Swelling After Knee Injury May Hinder Healing 2
... Pectoralis Implants come in three styles. ... is by far the most popular style. ... and are packaged and sold individually, not ... that they are each made for a ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... in the IQmark family elevates your ECG and ... portability, cost-savings and efficient patient care. The IQmark ... the office, clinics and medical centers as well ... used in conjunction with the IQmark Digital ECG ...
24-hour full disclosure , Input range: 5mV , Analog bandwidth: 0.05 to 100Hz (3dB) , Common mode rejection ratio: 60dB , Dimensions: 4.46in. x 2.75in. x 1.02in. (113mm x 70mm x 26mm) , We...
Medicine Products: